Skip to main content

Advertisement

SpringerLink
Log in

Impact of Statins on the Coagulation Status of Type 2 Diabetes Patients Evaluated by a Novel Thrombin-Generation Assay

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Purpose

Dyslipidemia is common in type 2 diabetes (T2D) and contributes to cardiovascular disease (CVD) by exacerbating atherosclerosis and hypercoagulability. Statins can stabilize atherosclerotic plaque and reduce prothrombotic status. In the present study we aimed to evaluate the coagulation activity and the effect of statins on procoagulant state of T2D patients using a novel activated protein C (APC)-dependent thrombin-generation assay.

Methods

Procoagulant status (by HemosIL ThromboPath (ThP) assay) and in vivo platelet activation (by plasma soluble (s)CD40L levels) were analyzed in a retrospective, cross-sectional study of 198 patients with long-standing T2D and 198 controls.

Results

Procoagulant status of T2D patients was enhanced when compared to control subjects (p < 0.0001). Similarly, sCD40L levels were increased in T2D (p < 0.0001). When testing ThP as the dependent variable in a multivariate regression model, sCD40L (p < 0.0001) and statin treatment (p = 0.019) were independent predictors of the procoagulant state of T2D patients. Subgroup analysis showed a significant improvement of coagulability in T2D patients on statins (p = 0.012).

Conclusions

The use of a standardized, easy-to-run, and commercially available APC-dependent thrombin-generation assay detected the presence of a procoagulant status in a large series of patients with long-standing T2D and demonstrated a significant impact of statins in the coagulation status of patients with T2D.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Krentz AJ. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab. 2003;5:S19–27.

    Article  PubMed  CAS  Google Scholar 

  2. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113–32.

    Article  PubMed  Google Scholar 

  3. Ferroni P, Basili S, Falco A, Davi G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost. 2004;2:1282–91.

    Article  PubMed  CAS  Google Scholar 

  4. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570–81.

    Article  PubMed  CAS  Google Scholar 

  5. Tripodi A, Branchi A, Chantarangkul V, Clerici M, Merati G, Artoni A, et al. Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. J Thromb Thrombolysis. 2011;31:165–72.

    Article  PubMed  CAS  Google Scholar 

  6. Palomo I, Alarcon M, Moore-Carrasco R, Argiles JM. Hemostasis alterations in metabolic syndrome (review). Int J Mol Med. 2006;18:969–74.

    PubMed  CAS  Google Scholar 

  7. Rubba P. Effects of atorvastatin on the different phases of atherogenesis. Drugs. 2007;67:17–27.

    Article  PubMed  CAS  Google Scholar 

  8. Ludwig S, Shen GX. Statins for diabetic cardiovascular complications. Curr Vasc Pharmacol. 2006;4:245–51.

    Article  PubMed  CAS  Google Scholar 

  9. Guadagni F, Albertini G, Barbanti P, Volterrani M, Palma E, Lancia A, et al. Foundation and Organization of a high-throughput technology-based Multidisciplinary and InterInstitutional Biobank at the IRCCS San Raffaele Pisana. Biopreserv Biobanking. 2010;7:201–2.

    Google Scholar 

  10. Guadagni F, Spila A, Nanni U, Somma P, Perrone V, De Angelis F, et al. Automated processing of biological samples. The experience of the InterInstitutional Multidisciplinary Biobank (BioBIM). Biopreserv Biobanking. 2010;7:230–1.

    Google Scholar 

  11. Wlodarczyk J, Sullivan D, Smith M. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. Am J Cardiol. 2008;102:1654–62.

    Article  PubMed  CAS  Google Scholar 

  12. Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105:69–76.

    Article  PubMed  CAS  Google Scholar 

  13. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106:3143–421.

    Google Scholar 

  14. Riondino S, Martini F, La Farina F, Spila A, Guadagni F, Ferroni P. Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions. Clin Biochem. 2010;43:666–70.

    Article  PubMed  CAS  Google Scholar 

  15. Toulon P, Smirnov M, Triscott M, Safa O, Biguzzi E, Bouziane K, et al. A new chromogenic assay (HemosIL ThromboPath) is sensitive to major prothrombotic risk factors affecting the protein C pathway. Results of a multicenter study. Thromb Res. 2009;124:137–43.

    Article  PubMed  CAS  Google Scholar 

  16. Adeghate E, Schattner P, Dunn E. An update on the etiology and epidemiology of diabetes mellitus. Ann NY Acad Sci. 2006;1084:1–29.

    Article  PubMed  Google Scholar 

  17. Ferroni P, La Farina F, Palmirotta R, Martini F, Raparelli V, Nigro C, et al. Predictive value of thrombopath determination in women with pregnancy complications. Clin Chim Acta. 2010;411:37–42.

    Article  PubMed  CAS  Google Scholar 

  18. Tripodi A, Legnani C, Lemma L, Cosmi B, Palareti G, Chantarangkul V, et al. Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. J Thromb Thrombolysis. 2010;30:215–9.

    Article  PubMed  Google Scholar 

  19. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood. 1996;87:3531–44.

    PubMed  Google Scholar 

  20. Krentz A. Type 2 diabetes and atherosclerotic cardiovascular disease: do they share common antecedents? Br J Diabetes Vasc Dis. 2002;2:370–8.

    Article  Google Scholar 

  21. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352:837–53.

  22. Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.

    Article  PubMed  CAS  Google Scholar 

  23. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.

    Article  PubMed  CAS  Google Scholar 

  24. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.

    Article  PubMed  CAS  Google Scholar 

  25. Colhoun HM, Thomason MJ, Mackness MI, Maton SM, Betteridge DJ, Durrington PN, et al. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med. 2002;19:201–11.

    Article  PubMed  CAS  Google Scholar 

  26. Vasudevan MM, Ballantyne CM. Advances in lipid testing and management in patients with diabetes mellitus. Endocr Pract. 2009;15:641–52.

    Article  PubMed  Google Scholar 

  27. Ceriello A, Quatraro A, Marchi E, Barbanti M, Dello Russo P, Lefebvre P, et al. The role of hyperglycaemia-induced alterations of antithrombin III and factor X activation in the thrombin hyperactivity of diabetes mellitus. Diabet Med. 1990;7:343–8.

    Article  PubMed  CAS  Google Scholar 

  28. Sauls DL, Banini AE, Boyd LC, Hoffman M. Elevated prothrombin level and shortened clotting times in subjects with type 2 diabetes. J Thromb Haemost. 2007;5:638–9.

    Article  PubMed  CAS  Google Scholar 

  29. Santilli F, Davi G, Consoli A, Cipollone F, Mezzetti A, Falco A, et al. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol. 2006;47:391–7.

    Article  PubMed  CAS  Google Scholar 

  30. Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation. 2004;109:2524–8.

    Article  PubMed  CAS  Google Scholar 

  31. Varo N, Libby P, Nuzzo R, Italiano J, Doria A, Schönbeck U. Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products. Diab Vasc Dis Res. 2005;2:81–7.

    Article  PubMed  Google Scholar 

  32. Neubauer H, Setiadi P, Günesdogan B, Pinto A, Börgel J, Mügge A. Influence of glycaemic control on platelet bound CD40-CD40L system, P-selectin and soluble CD40 ligand in Type 2 diabetes. Diabet Med. 2010;27:384–90.

    Article  PubMed  CAS  Google Scholar 

  33. Bláha V, Andrýs C, Smahelová A, Knízek J, Hyspler R, Solichová D, et al. Effect of atorvastatin on soluble CD14, CD40 Ligand, sE- and sP-selectins and MCP-1 in patients with type 2 diabetes mellitus: relationship to cholesterol turnover. Pharmacol Res. 2006;54:421–8.

    Article  PubMed  Google Scholar 

  34. Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual AL, Bernal MR, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation. 2003;107:2664–9.

    Article  PubMed  CAS  Google Scholar 

  35. Santini E, Madec S, Corretti V, Ferrannini E, Solini A. Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients. J Endocrinol Invest. 2008;31:660–5.

    PubMed  CAS  Google Scholar 

  36. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation. 2004;110:386–91.

    Article  PubMed  CAS  Google Scholar 

  37. Jaumdally RJ, Lip GY, Varma C, Blann AD. Impact of high-dose atorvastatin on endothelial, platelet, and angiogenic indices: effect of ethnicity, cardiovascular disease, and diabetes. Angiology. 2011;62:571–8.

    Article  PubMed  CAS  Google Scholar 

  38. Kannel WB. Overview of atherosclerosis. Clin Ther. 1998;20:B2–B17.

    Article  PubMed  Google Scholar 

  39. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol. 2005;25:287–94.

    Article  PubMed  CAS  Google Scholar 

  40. Arnaboldi L, Corsini A. Do structural differences in statins correlate with clinical efficacy? Curr Opin Lipidol. 2010;21:298–304.

    Article  PubMed  CAS  Google Scholar 

  41. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–25.

    Article  PubMed  CAS  Google Scholar 

  42. Avogaro A, Guida P, Giorda C, Mannucci E, Medea G, Comaschi M, et al. The under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy. Nutr Metab Cardiovasc Dis. 2007;17:32–40.

    Article  PubMed  CAS  Google Scholar 

  43. Kumar A, Singh V. Atherogenic dyslipidemia and diabetes mellitus: what’s new in the management arena? Vasc Health. Risk Manag. 2010;6:665–9.

    CAS  Google Scholar 

Download references

Acknowledgments

This work was partially supported by the Italian Ministry of Health Grant ACC-WP 3/1b and MERIT RBNE08NKH7. The authors wish to thank Francesco De Angelis and Vincenzino Perrone (InterInstitutional Multidisciplinary BioBank, Department of Laboratory Medicine and Advanced Biotechnologies, IRCCS San Raffaele, Rome, Italy), for their excellent technical assistance.

Declaration of Competing Interests

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine and Advanced Biotechnologies, IRCCS San Raffaele Pisana, Via della Pisana, 235, 00163, Rome, Italy

    P. Ferroni, D. Della-Morte, F. Martini, F. La Farina, R. Palmirotta & F. Guadagni

  2. InterInstitutional Multidisciplinary Biobank (BioBIM), IRCCS San Raffaele, Rome, Italy

    D. Della-Morte, M. G. Valente & F. Guadagni

  3. Diabetes Research Institute, Rome, Italy

    D. Della-Morte & F. Guadagni

  4. Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL, USA

    D. Della-Morte & T. Rundek

  5. Diabetes Research Institute, University of Miami, Miami, FL, USA

    A. Pileggi, L. F. Meneghini & C. Ricordi

  6. DeWitt-Daughtry Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA

    A. Pileggi & C. Ricordi

  7. Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL, USA

    A. Pileggi & C. Ricordi

  8. Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL, USA

    C. Ricordi

Authors
  1. P. Ferroni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Della-Morte
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Pileggi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. G. Valente
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Martini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. La Farina
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Palmirotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L. F. Meneghini
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. T. Rundek
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C. Ricordi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. F. Guadagni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Ferroni.

Additional information

P. Ferroni, D. Della-Morte for equal contribution

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ferroni, P., Della-Morte, D., Pileggi, A. et al. Impact of Statins on the Coagulation Status of Type 2 Diabetes Patients Evaluated by a Novel Thrombin-Generation Assay. Cardiovasc Drugs Ther 26, 301–309 (2012). https://doi.org/10.1007/s10557-012-6388-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-012-6388-y

Key words

Search

Navigation